Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Compare 3 Dose Levels Of CP-690,550 Versus Placebo, Administered Orally Twice Daily (BID) For 6 Weeks, In The Treatment Of The Signs And Symptoms Of Subjects With Active Rheumatoid Arthritis
Brief Summary: The study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550 monotherapy (5 mg, 15 mg, and 30 mg twice daily \[BID\]) versus placebo administered over 6 weeks for the treatment of the signs and symptoms of subjects with active rheumatoid arthritis (RA).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690-550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690-550 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: CP-690-550 | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 6; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 7; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690-550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690-550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: CP-690-550; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 7
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1
C: Arm Label: Tocilizumab 162 mg sc; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab 162 mg | Arm Label: Placebo sc; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tocilizumab 162 mg; Assigned to Arm(s): Tocilizumab 162 mg sc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo sc
D: Arm Label: 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 15 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 15 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 30 mg BID | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D